Member Info for Marcbought

Forgot about that guy, I guess he has his tail between his legs at the moment. Will be back when the company starts ramping though.

Have to hold my hands up though, I got one thing wrong, the raise price was over 15% lower than even I expected.

There it is, the massive raise with no news in the meantime. And even worst:

Waiting til the price is already on its arse before raising even lower, presumably to let the participants in cheaply.

Directors subscribing for absolutely pitiful amounts.

Warrants will cap any near term movements.

100% diabolical history.

What more flags do you need for a lifestyle company?

Wow what a touchy board. I post a single AI output, not a single word written by me personally and everyone jumps on me like a criminal. Says a lot about confidence levels here doesn't it?

That ain't output was broadly very accurate too. If anyone is capable of actually arguing the points rather than attacking me, that might be a more convincing method

True Positives (Definite Facts)

​Clinical Status: AVA6103 has officially moved from a laboratory concept into the clinic; the Phase 1 "FOCUS-01" trial is now active and the first patient has been treated.

​Expansion of Indications: The trial is not limited to one cancer; it is recruiting for multiple solid tumors, specifically including colorectal cancer and HR+ breast cancer.

​Platform Utility: The "pre|CISION" platform has successfully demonstrated its dual-payload capability in live models (in vivo). This proves the technology can carry and release two different cancer-killing drugs simultaneously, which is a technical milestone for the company's "Gen Three" pipeline.

​Benchmarking: In head-to-head preclinical tests, AVA6103 achieved a maximal tumor concentration (Cmax) over 10 times higher than the leading antibody-drug conjugate (ADC), Enhertu.

​Negatives (Downsides or Risks)

​The "Preclinical" Gap: Almost all the "robust activity" and "favorable kinetics" mentioned are based on animal/PDX models. Success in mice frequently fails to translate to the same efficacy or safety in humans.

​Comparator Method: The comparison to Enhertu used an AI-driven synthetic comparator arm. While innovative, this is not a clinical head-to-head trial; it is a computer-simulated benchmark against historical data, which carries inherent modeling bias.

​Safety Uncertainty: While the goal is "minimizing systemic toxicity," the actual safety profile in humans will not be known until the Phase 1 data is released (expected late H2 2026).

​Speculative or Fluff

​"Considerable Difference to Patients": This is CEO-speak. Until the drug passes Phase 2 and 3 trials (years away), any claim about the impact on patient outcomes is speculative.

​"Increased Probability of Success": The RNS claims the new data "significantly increases" the chance of trial success. In reality, pharmaceutical success rates remain statistically low until human data proves otherwise.

​"Broadening Utility": Statements regarding the platform's potential to deliver "many therapeutic modalities" are visionary but lack concrete evidence or specific product timelines at this stage

It's not shares in issue that matters for how fast it moves, it's the market cap.

Too many fickle investors, looks like it will fall back to where it started yesterday now, but I'm expecting news in the next month

Very nice rise off the back of what would be a meaningless RNs in a lot of companies but potentially good sign here. I'd guess a few weeks of yoyo-ing here then hopefully a deal. Will be a traders dream of you're brave enough!

Easy money from here as the cheapest shell on the main market. 4x anyone?

You don't make a new board appointment in "down time" unless something is cooking near term! Watch this spike in next month

So now it's nothing until summer? And then when we get to summer it will be early autumn and then...

New book out: How to Take an Exciting, Rapidly Expanding, Market-Leading Company and Put it on its Arse in just 18 Months - the Mo Khan Story.

Sadly most of the pages are empty because Mo refused to comment.

Id say mo is having a shocker but has he ever actually been good? He has complete disdain for you lot and hides away constantly. Not a CEO I would want near a publicly limited company because his shareholder relations are non existent and you can see why, his CV is actually crap.

25 years ago he was a project manager, spent 20 years in a company and was never an MD or CEO, never even worked at a listed company, spent 5 of the most recent years in a consultancy capacity then joined hvivo with no understanding or experience that shareholder relations is a big and important part of his role. Got thrown in the deep end by Cathal, looked nervy on a number of investor calls then when Cathal left seemed to have decided he would do the bare minimum on that front going forward. Clearly incapable of getting anything over the line and hides away as the share price drifts 80% down, saying nothing whatsoever about the dire performance of the company under his leadership. He's a charlatan and it's about time you lot held him accountable.

Says the guy who's recent history is 100% tym. Clearly makes up your entire portfolio. You know it's strange because you recently claimed to have over £1MILLION in rolls royce yet you don't make a single post there, yet here you are stressing over a micro gap speculative miner and replying within seconds to every post. I think we may have a littttttle bit of a fantasist in our midsts.

How much is the RNs for a placing going to hurt you? Not only a bruised ego but your life savings just halved, how did you get so over exposed in a company like tym with no money, no income, and a proven record of 100% failure?

Not caring about views that oppose yours is one of the cardinal sins of investing. If you want to ignore all other points of view and just insist you are right on everything, you will come a cropper and likely very quickly.

I was posting in February about the poor financial position, the price was 0.12 at the time ....its 0.76 now, over 35% down while you protested all the way about how fantastic the company was and how there was going to be some massive unexpected JV announcement. I posted facts while you posted fluff and how has that worked out this last month?

Now the AGM today has finally given them the rights to do another placing, which the company has already written in black and white to say they will need to do, but again you believe there will be no fundraise in the near future. More fluff.

I just hope a couple of people were saved by my posts a month back.

There is a time and a place to own speculative miners and right before a known rise is the worst possible.

Squeaky bum time for holders now. The worst thing is these big price falls are BEFORE the raise and the raise will have to be at a discount, regardless what level the price is at at that moment.

Nothing exciting about a guaranteed massive placing and no reason to hold prior to it, other than stupidity

So here we are, no "Wednesday announcement on a joint venture" as you (and you alone) were thinking, sharedealer.

Tomorrow is the general meeting to approve more placings going forward, which the company has specifically said they need to do just to continue as a going concern. When will the placing come? Let's see if my prediction of within two weeks plays out. Then we have to ask at what price? I've predicted 0.06, feel free to make your own guess guys, but it will definitely be a discount to the share price now so I have elected to sell out and buy back cheaper on the fall

So all that nonsense arguing and even you can't say you don't think there will be a placing soon, says it all doesn't it.

That was a simple question share dealer, I'm surprised you dodged it:

Just to check, you think there will be no fundraise in the near future?

Ok, so just to check, you think there will be no fundraise in the near future?